277 related articles for article (PubMed ID: 11848649)
1. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure stability in a normotensive population during intake of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 g gestodene.
Endrikat J; Gerlinger C; Cronin M; Ruebig A; Schmidt W; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):159-66. PubMed ID: 11763980
[TBL] [Abstract][Full Text] [Related]
3. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
Ferreira AC; Montes MB; Franceschini SA; Toloi MR
Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
[TBL] [Abstract][Full Text] [Related]
4. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
Yildizhan R; Yildizhan B; Adali E; Yoruk P; Birol F; Suer N
Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
Halbe HW; de Melo NR; Bahamondes L; Petracco A; Lemgruber M; de Andrade RP; da Cunha DC; Guazelli CA; Baracat EC
Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
[TBL] [Abstract][Full Text] [Related]
6. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
Uchikova E; Terzhumanov R; Milchev N; Iacheva T
Akush Ginekol (Sofiia); 2004; 43(6):19-23. PubMed ID: 15669648
[TBL] [Abstract][Full Text] [Related]
7. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
Bilotta P; Favilli S
Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
[TBL] [Abstract][Full Text] [Related]
9. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
Fuchs N; Düsterberg B; Weber-Diehl F; Mühe B
Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of a low-dose contraceptive--Femodene].
Rachev E; Damianov L; Dukovski A; Katsarova M
Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with a low-dose oral contraceptive containing gestodene.
Düsterberg B; Brill K
Adv Contracept; 1990 Dec; 6 Suppl():37-49; discussion 50. PubMed ID: 2291446
[TBL] [Abstract][Full Text] [Related]
12. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
13. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
Nappi C; Di Spiezio Sardo A; Greco E; Tommaselli GA; Giordano E; Guida M
Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
[TBL] [Abstract][Full Text] [Related]
14. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Barbosa IC; Filho CI; Faggion D; Baracat EC
Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
[TBL] [Abstract][Full Text] [Related]
15. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
16. [The desogestrel-ethinyl estradiol combination and overweight: current data].
Rubio Lotvin B
Ginecol Obstet Mex; 1995 Nov; 63():483-6. PubMed ID: 8537039
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of body composition during low-dose estrogen oral contraceptives treatment.
Franchini M; Caruso C; Nigrelli S; Poggiali C
Acta Eur Fertil; 1995; 26(2):69-73. PubMed ID: 9098463
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal contraception has no effect on the atherogenicity of blood lipids: results of a prospective open-label multicenter study in 1321 patients].
Kunz J; Jaeger A
Praxis (Bern 1994); 1996 Jan; 85(1-2):3-8. PubMed ID: 8571024
[TBL] [Abstract][Full Text] [Related]
19. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
20. Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo.
Loncar D; Milosević-Djordjević O; Zivanović A; Grujicić D; Arsenijević S
Contraception; 2004 Apr; 69(4):327-31. PubMed ID: 15033409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
